Deerfield Management Company, L.P. (Series C) Nuvation Bio Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.04 Billion
- Q4 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 20,166 shares of NUVB stock, worth $38,113. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,166Holding current value
$38,113% of portfolio
0.0%Shares
7 transactions
Others Institutions Holding NUVB
# of Institutions
164Shares Held
151MCall Options Held
1.2KPut Options Held
223K-
Decheng Capital LLC Menlo Park, CA26MShares$49.1 Million14.81% of portfolio
-
Black Rock Inc. New York, NY16.2MShares$30.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.7MShares$29.7 Million0.0% of portfolio
-
Omega Fund Management, LLC Boston, MA13.1MShares$24.7 Million53.05% of portfolio
-
Octagon Capital Advisors LP New York, NY9.2MShares$17.4 Million5.46% of portfolio
About Nuvation Bio Inc.
- Ticker NUVB
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 217,244,000
- Market Cap $411M
- Description
- Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...